The relationship of the extra-cellular matrix (ECM) and secreted proteins to intra-cellular functions has an important impact on disease progression. The tissue inhibitors of metalloproteinases (TIMPs), of which there are four, are known for their broad metalloprotease inhibitory abilities. TIMP-1 has been widely studied as an inhibitor of matrix metalloproteinases (MMPs) and therefore as a molecule that prevents ECM degradation and proteolytic cleavage of extra-cellular molecules, processes thought to be critical for tumor invasion and metastasis. However, TIMP-1 has shown in the clinic to have increased expression in cases of disease progression; especially, it is associated with poor prognosis in many types of cancer. Hence, there may be oncogenic functions of TIMP-1 that drives cancer progression. We have been studying non-MMP-inhibitory functions of TIMP-1 to better understand TIMP-1 as a pleiotropic molecule and its role in disease development. In this area, we and others have shown important signaling cues mediated by TIMP-1 including anti-apoptotic signaling and epithelial-to-mesenchymal transition (EMT) induction; which may play a role in cancer progression. Our current research has included direct protein-protein interaction analysis using protein complementation assay (PCA) of the interaction of TIMP-1 and CD63. CD63 is a tetraspanin, whose major functional properties are not well understood. We have previously identified CD63 as a non-MMP protein and a transmembrane (TM) protein with which TIMP-1 has direct interaction, resulting in intra-cellular signal transduction for cell survival and EMT. We have characterized the interaction between TIMP-1 and CD63 including identification of their respective binding sites. Importantly, we have also demonstrated a robust interaction for TIMP-1 and CD63 at the cell surface in live cells.
In addition, we have utilized PCA methodology in studying the relationship of CD63 with an important disease-related MMP, namely membrane type-1-MMP (MT1-MMP). This MMP is known to be upregulated in cancer progression and has been shown to have interaction with CD63 in previous studies. As we did for TIMP-1, we have mapped the interacting sites of MT1-MMP and CD63. As well, to better understand the relationship of TIMP-1 and MT1-MMP to the binding of each other to CD63 we have studied these three proteins together. We observe that TIMP-1 and MT1-MMP are not compatible in CD63 binding but they compete one with another for interaction with CD63. Our study presents a paradigm shift in our understanding of TIMP-1 functions; we show that the C-terminal domain of TIMP-1, independent of its MMP-inhibitory domain, interacts with CD63 and induces intracellular signal transduction. Importantly, these interactions compete for MT1-MMP binding with CD63, known to mediate endocytosis and degradation of MT1-MMP. Thus, TIMP-1 interaction with CD63 results in MT1-MMP stabilization/accumulation on the cell surface, leading to activation of the MT1-MMP/MMP-2 proteolytic cascade. Our finding provides valuable information for the design of therapeutic intervention of TIMP-1's oncogenic activity while preserving its tumor suppressive MMP-inhibitory functions.
","abstract_html":"<p>The relationship of the extra-cellular matrix (ECM) and secreted proteins to intra-cellular functions has an important impact on disease progression. The tissue inhibitors of metalloproteinases (TIMPs), of which there are four, are known for their broad metalloprotease inhibitory abilities. TIMP-1 has been widely studied as an inhibitor of matrix metalloproteinases (MMPs) and therefore as a molecule that prevents ECM degradation and proteolytic cleavage of extra-cellular molecules, processes thought to be critical for tumor invasion and metastasis. However, TIMP-1 has shown in the clinic to have increased expression in cases of disease progression; especially, it is associated with poor prognosis in many types of cancer. Hence, there may be oncogenic functions of TIMP-1 that drives cancer progression. We have been studying non-MMP-inhibitory functions of TIMP-1 to better understand TIMP-1 as a pleiotropic molecule and its role in disease development. In this area, we and others have shown important signaling cues mediated by TIMP-1 including anti-apoptotic signaling and epithelial-to-mesenchymal transition (EMT) induction; which may play a role in cancer progression. Our current research has included direct protein-protein interaction analysis using protein complementation assay (PCA) of the interaction of TIMP-1 and CD63. CD63 is a tetraspanin, whose major functional properties are not well understood. We have previously identified CD63 as a non-MMP protein and a transmembrane (TM) protein with which TIMP-1 has direct interaction, resulting in intra-cellular signal transduction for cell survival and EMT. We have characterized the interaction between TIMP-1 and CD63 including identification of their respective binding sites. Importantly, we have also demonstrated a robust interaction for TIMP-1 and CD63 at the cell surface in live cells. </p> <p>In addition, we have utilized PCA methodology in studying the relationship of CD63 with an important disease-related MMP, namely membrane type-1-MMP (MT1-MMP). This MMP is known to be upregulated in cancer progression and has been shown to have interaction with CD63 in previous studies. As we did for TIMP-1, we have mapped the interacting sites of MT1-MMP and CD63. As well, to better understand the relationship of TIMP-1 and MT1-MMP to the binding of each other to CD63 we have studied these three proteins together. We observe that TIMP-1 and MT1-MMP are not compatible in CD63 binding but they compete one with another for interaction with CD63. Our study presents a paradigm shift in our understanding of TIMP-1 functions; we show that the C-terminal domain of TIMP-1, independent of its MMP-inhibitory domain, interacts with CD63 and induces intracellular signal transduction. Importantly, these interactions compete for MT1-MMP binding with CD63, known to mediate endocytosis and degradation of MT1-MMP. Thus, TIMP-1 interaction with CD63 results in MT1-MMP stabilization/accumulation on the cell surface, leading to activation of the MT1-MMP/MMP-2 proteolytic cascade. Our finding provides valuable information for the design of therapeutic intervention of TIMP-1's oncogenic activity while preserving its tumor suppressive MMP-inhibitory functions.</p>","abstract_has_math":false,"creators":["Warner, Richard B."],"institution":null,"degree_name":"Ph.D.","degree_level":"Open Access Dissertation","degree_discipline":"Cancer Biology","degree_department":null,"school":null,"contributors":["Hyeong-Reh C. Kim"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013-01-01T08:00:00Z","date_published":"2013-01-01T08:00:00Z","updated_at":"2026-07-24T05:59:33Z","subjects":["CD63","MT1-MMP","TIMP-1","Oncology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.wayne.edu/oa_dissertations/864","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Hyeong-Reh C. Kim"]},{"key":"dc:creator","label":"Author","values":["Warner, Richard B."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2013-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Cancer Biology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Open Access Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["CD63","MT1-MMP","TIMP-1","Oncology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.wayne.edu/oa_dissertations/864"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The relationship of the extra-cellular matrix (ECM) and secreted proteins to intra-cellular functions has an important impact on disease progression. The tissue inhibitors of metalloproteinases (TIMPs), of which there are four, are known for their broad metalloprotease inhibitory abilities. TIMP-1 has been widely studied as an inhibitor of matrix metalloproteinases (MMPs) and therefore as a molecule that prevents ECM degradation and proteolytic cleavage of extra-cellular molecules, processes thought to be critical for tumor invasion and metastasis. However, TIMP-1 has shown in the clinic to have increased expression in cases of disease progression; especially, it is associated with poor prognosis in many types of cancer. Hence, there may be oncogenic functions of TIMP-1 that drives cancer progression. We have been studying non-MMP-inhibitory functions of TIMP-1 to better understand TIMP-1 as a pleiotropic molecule and its role in disease development. In this area, we and others have shown important signaling cues mediated by TIMP-1 including anti-apoptotic signaling and epithelial-to-mesenchymal transition (EMT) induction; which may play a role in cancer progression. Our current research has included direct protein-protein interaction analysis using protein complementation assay (PCA) of the interaction of TIMP-1 and CD63. CD63 is a tetraspanin, whose major functional properties are not well understood. We have previously identified CD63 as a non-MMP protein and a transmembrane (TM) protein with which TIMP-1 has direct interaction, resulting in intra-cellular signal transduction for cell survival and EMT. We have characterized the interaction between TIMP-1 and CD63 including identification of their respective binding sites. Importantly, we have also demonstrated a robust interaction for TIMP-1 and CD63 at the cell surface in live cells.
In addition, we have utilized PCA methodology in studying the relationship of CD63 with an important disease-related MMP, namely membrane type-1-MMP (MT1-MMP). This MMP is known to be upregulated in cancer progression and has been shown to have interaction with CD63 in previous studies. As we did for TIMP-1, we have mapped the interacting sites of MT1-MMP and CD63. As well, to better understand the relationship of TIMP-1 and MT1-MMP to the binding of each other to CD63 we have studied these three proteins together. We observe that TIMP-1 and MT1-MMP are not compatible in CD63 binding but they compete one with another for interaction with CD63. Our study presents a paradigm shift in our understanding of TIMP-1 functions; we show that the C-terminal domain of TIMP-1, independent of its MMP-inhibitory domain, interacts with CD63 and induces intracellular signal transduction. Importantly, these interactions compete for MT1-MMP binding with CD63, known to mediate endocytosis and degradation of MT1-MMP. Thus, TIMP-1 interaction with CD63 results in MT1-MMP stabilization/accumulation on the cell surface, leading to activation of the MT1-MMP/MMP-2 proteolytic cascade. Our finding provides valuable information for the design of therapeutic intervention of TIMP-1's oncogenic activity while preserving its tumor suppressive MMP-inhibitory functions.
"]},{"key":"dc:title","label":"Title","values":["Analysis Of The Structure And Function Of A Timp-1/cd63 Complex And Its Relationship To An Mt1-Mmp/cd63 Complex"]}]}],"canonical_facts":{"dc:contributor":["Hyeong-Reh C. Kim"],"dc:creator":["Warner, Richard B."],"dc:date.available":["2013-01-01T08:00:00Z"],"dc:description.abstract":["The relationship of the extra-cellular matrix (ECM) and secreted proteins to intra-cellular functions has an important impact on disease progression. The tissue inhibitors of metalloproteinases (TIMPs), of which there are four, are known for their broad metalloprotease inhibitory abilities. TIMP-1 has been widely studied as an inhibitor of matrix metalloproteinases (MMPs) and therefore as a molecule that prevents ECM degradation and proteolytic cleavage of extra-cellular molecules, processes thought to be critical for tumor invasion and metastasis. However, TIMP-1 has shown in the clinic to have increased expression in cases of disease progression; especially, it is associated with poor prognosis in many types of cancer. Hence, there may be oncogenic functions of TIMP-1 that drives cancer progression. We have been studying non-MMP-inhibitory functions of TIMP-1 to better understand TIMP-1 as a pleiotropic molecule and its role in disease development. In this area, we and others have shown important signaling cues mediated by TIMP-1 including anti-apoptotic signaling and epithelial-to-mesenchymal transition (EMT) induction; which may play a role in cancer progression. Our current research has included direct protein-protein interaction analysis using protein complementation assay (PCA) of the interaction of TIMP-1 and CD63. CD63 is a tetraspanin, whose major functional properties are not well understood. We have previously identified CD63 as a non-MMP protein and a transmembrane (TM) protein with which TIMP-1 has direct interaction, resulting in intra-cellular signal transduction for cell survival and EMT. We have characterized the interaction between TIMP-1 and CD63 including identification of their respective binding sites. Importantly, we have also demonstrated a robust interaction for TIMP-1 and CD63 at the cell surface in live cells.
In addition, we have utilized PCA methodology in studying the relationship of CD63 with an important disease-related MMP, namely membrane type-1-MMP (MT1-MMP). This MMP is known to be upregulated in cancer progression and has been shown to have interaction with CD63 in previous studies. As we did for TIMP-1, we have mapped the interacting sites of MT1-MMP and CD63. As well, to better understand the relationship of TIMP-1 and MT1-MMP to the binding of each other to CD63 we have studied these three proteins together. We observe that TIMP-1 and MT1-MMP are not compatible in CD63 binding but they compete one with another for interaction with CD63. Our study presents a paradigm shift in our understanding of TIMP-1 functions; we show that the C-terminal domain of TIMP-1, independent of its MMP-inhibitory domain, interacts with CD63 and induces intracellular signal transduction. Importantly, these interactions compete for MT1-MMP binding with CD63, known to mediate endocytosis and degradation of MT1-MMP. Thus, TIMP-1 interaction with CD63 results in MT1-MMP stabilization/accumulation on the cell surface, leading to activation of the MT1-MMP/MMP-2 proteolytic cascade. Our finding provides valuable information for the design of therapeutic intervention of TIMP-1's oncogenic activity while preserving its tumor suppressive MMP-inhibitory functions.
"],"dc:identifier":["https://digitalcommons.wayne.edu/oa_dissertations/864"],"dc:subject":["CD63","MT1-MMP","TIMP-1","Oncology"],"dc:title":["Analysis Of The Structure And Function Of A Timp-1/cd63 Complex And Its Relationship To An Mt1-Mmp/cd63 Complex"],"thesis:degree_discipline":["Cancer Biology"],"thesis:degree_level":["Open Access Dissertation"],"thesis:degree_name":["Ph.D."]},"updated_at":"2026-07-24T05:59:33Z"}